Drug Information

Drug General Information
Drug ID
D04YEW
Former ID
DIB005258
Drug Name
Tarafenacin
Synonyms
SVT-40776; Muscarinic M3 receptor antagonist (overactive bladder), SALVAT
Drug Type
Small molecular drug
Indication Overactive bladder disorder [ICD9: 188, 596.51; ICD10:C67, N32.81] Phase 2 [523669]
Company
Laboratorios SALVAT SA
Formula
C21H20F4N2O2
Canonical SMILES
C1N2CC[C@@H]([C@H]1OC(=O)N(c1cc(ccc1)F)Cc1cc(c(c(c1)F)F<br />)F)CC2
CAS Number
CAS 385367-47-5
PubChem Compound ID
25147683
Target and Pathway
Target(s) Muscarinic acetylcholine receptor M3 Target Info Antagonist [529966]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Cholinergic synapse
Regulation of actin cytoskeleton
Insulin secretion
Salivary secretion
Gastric acid secretion
Pancreatic secretion
PANTHER Pathway Alzheimer disease-amyloid secretase pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Muscarinic acetylcholine receptor 1 and 3 signaling pathway
PathWhiz Pathway Gastric Acid Production
Reactome Muscarinic acetylcholine receptors
Acetylcholine regulates insulin secretion
G alpha (q) signalling events
WikiPathways Monoamine GPCRs
Calcium Regulation in the Cardiac Cell
Regulation of Actin Cytoskeleton
GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
Integration of energy metabolism
GPCR ligand binding
GPCR downstream signaling
GPCRs, Other
References
Ref 523669ClinicalTrials.gov (NCT01458197) A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.. U.S. National Institutes of Health.
Ref 529966In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder. Br J Pharmacol. 2009 Mar;156(5):807-17.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.